AZN - AstraZeneca's Enhertu granted approval for HER-2 positive tumor-agnostic indications
2024-04-05 16:14:43 ET
More on AstraZeneca, Daiichi Sankyo
- What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals
- 5 Reasons AstraZeneca Stock Can Rise In 2024
- AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript
- AstraZeneca Imfinzi improves survival in late-stage lung cancer trial
- FDA accepts Daiichi Sankyo-AstraZeneca's breast cancer therapy for review